News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

mHealth Remains Popular Due to Shift towards Value-Based Medicine

June 21, 2017
Article

Pharmaceutical Executive

 Mobile health (mHealth) has become progressively popular globally and offers various services to the healthcare industry-including data collection and remote patient monitoring-and is predicted to increase as the industry continues to shift toward value-based medicine, according to business intelligence provider GBI Research.

 

The company’s latest report states that mHealth solutions and services are a reality due to advancement in new devices, the expansion of communication network coverage, and the reduction in the retail price of wireless technologies. The market drive derives from a need for more cost-effective means to deliver healthcare, a need to demonstrate the value and effectiveness of treatments, and increasing support from healthcare professionals and reimbursement entities for mHealth solutions.

 

The need for more cost-effective means to deliver healthcare is regarded as the most important growth driver in the mHealth market, followed by the increasing need to demonstrate the value and effectiveness of treatments and by increasing support from healthcare professionals and reimbursement entities for mHealth solutions.

Recent Videos
Unique Challenges in Repurposing Drugs for Addiction Treatment
Unique Challenges in Repurposing Drugs for Addiction Treatment
Hybrid Hub Models for the Patient Journey
Hybrid Hub Models for the Patient Journey
GLP-1 Drug Repurposing for Addiction Disorders Hampered by High Costs and Legal Hurdles
GLP-1 Drug Repurposing for Addiction Disorders Hampered by High Costs and Legal Hurdles
Quyen Nguyen on Helping Surgeons Preserve Nerve Function in Surgery
Quyen Nguyen on Helping Surgeons Preserve Nerve Function in Surgery
Asembia 2025: GLP-1 Drugs Reshape Reimbursement and Coverage Models
Asembia 2025: GLP-1 Drugs Reshape Reimbursement and Coverage Models
Asembia 2025: Digital Health and Biosimilars Shape the Future of Pharmacy
Asembia 2025: Digital Health and Biosimilars Shape the Future of Pharmacy
Patient Services: A Marathon, Not A Sprint
Patient Services: A Marathon, Not A Sprint
Asembia 2025: Tracking Long-Term Outcomes Key to Advanced Therapy Value
Asembia 2025: Tracking Long-Term Outcomes Key to Advanced Therapy Value
Herspiegel Consulting Dives Into the Value Narrative
Herspiegel Consulting Dives Into the Value Narrative
Asembia 2025: Why AI Could Be the Key to Solving Access Challenges in Healthcare
Asembia 2025: Why AI Could Be the Key to Solving Access Challenges in Healthcare
Related Content
Advertisement

Julius Ramirez

A Chaotic Moment for Pharma Marketing: Q&A with Julius Ramirez

Mike Hollan
May 13th 2025
Article

Stricter regulations on a fragmented media landscape is forcing the industry to rethink marketing.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


How Does the Shift to Early-Stage M&A Change Due Diligence?

How Does the Shift to Early-Stage M&A Change Due Diligence?

Kirsten Jacobs, PhD ;Eva Keck
May 12th 2025
Article

A well-defined scientific and strategic approach is critical for buyers in this dealmaking setting.


Beyond the Prescription: Pharma's Role in Digital Health Conversations

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
April 1st 2025
Podcast

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.


Stock.adobe.com

White House Unveils Pharma Most-Favored-Nation Executive Order

Mike Hollan
May 12th 2025
Article

The order pushes drug companies to reduce drug prices in the United States to fall in line with other countries around the world.


The Three Pillars of Pharma’s New Commercial Model

The Three Pillars of Pharma’s New Commercial Model

Saby Mitra
May 12th 2025
Article

Identifying the priorities that translate to strong business outcomes—and separating the top performers from the average brands.

Related Content
Advertisement

Julius Ramirez

A Chaotic Moment for Pharma Marketing: Q&A with Julius Ramirez

Mike Hollan
May 13th 2025
Article

Stricter regulations on a fragmented media landscape is forcing the industry to rethink marketing.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


How Does the Shift to Early-Stage M&A Change Due Diligence?

How Does the Shift to Early-Stage M&A Change Due Diligence?

Kirsten Jacobs, PhD ;Eva Keck
May 12th 2025
Article

A well-defined scientific and strategic approach is critical for buyers in this dealmaking setting.


Beyond the Prescription: Pharma's Role in Digital Health Conversations

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
April 1st 2025
Podcast

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.


Stock.adobe.com

White House Unveils Pharma Most-Favored-Nation Executive Order

Mike Hollan
May 12th 2025
Article

The order pushes drug companies to reduce drug prices in the United States to fall in line with other countries around the world.


The Three Pillars of Pharma’s New Commercial Model

The Three Pillars of Pharma’s New Commercial Model

Saby Mitra
May 12th 2025
Article

Identifying the priorities that translate to strong business outcomes—and separating the top performers from the average brands.

Advertisement
Advertisement
Advertisement
x
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.